A
Ana Barac
Researcher at Georgetown University
Publications - 158
Citations - 8236
Ana Barac is an academic researcher from Georgetown University. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 30, co-authored 126 publications receiving 5347 citations. Previous affiliations of Ana Barac include MedStar Georgetown University Hospital & MedStar Washington Hospital Center.
Papers
More filters
Journal ArticleDOI
Assessing Heart Failure vs Lymphoma Treatment Risks and Benefits-It Takes Two to Tango.
TL;DR: The JAMA Cardiology journal published by the American Medical Association (AMA) as mentioned in this paper is the most widely cited journal in the field of Cardiology and has a large number of publications.
Journal ArticleDOI
Heart Failure Risk Prediction in Childhood Cancer Survivors: Where Is Our Crystal Ball?
Elizabeth C. Bluhm,Ana Barac +1 more
TL;DR: A study derived and tested a new prediction model for the risk of heart failure among survivors of childhood cancer and uses logistic regression to identify the strongest predictors of CHF in young cancer survivors.
Journal ArticleDOI
Digital Technologies in Cardiac Rehabilitation: A Science Advisory From the American Heart Association
Jessica R. Golbus,Francisco Lopez-Jimenez,Ana Barac,William K. Cornwell,Patrick Dunn,Daniel E. Forman,Seth S. Martin,Erica N. Schorr,Marta Supervia +8 more
TL;DR: The American Heart Association science advisory was assembled to guide the development and implementation of digital cardiac rehabilitation interventions that can be translated effectively into clinical care, improve health outcomes, and promote health equity as mentioned in this paper .
Journal ArticleDOI
The effect of catheter‐directed thrombolytic use on readmission rates and in‐hospital outcomes among cancer patients with venous thromboembolism in the United States
Avirup Guha,Grant McKinley,Amit K. Dey,Rebecca R. Carter,P. Elliott Miller,Abhishek Deshmukh,Raja Zaghlol,Ana Barac,Nihar R. Desai,Daniel Addison +9 more
TL;DR: The impacts of cancer on the likelihood for readmission after a VTE‐targeted procedure and the importance of avoiding unnecessary surgery are assessed.
Journal ArticleDOI
Abstract 11850: Association Between SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Antineoplastic Therapy Associated Cardiomyopathy and Heart Failure
Vennela Avula,Garima Sharma,Mikhail Kosiborod,Muthiah Vaduganathan,Tomas G. Neilan,Teresa López-Fernández,Susan Dent,Lauren A. Baldassarre,Marielle Scherrer-Crosbie,Ana Barac,Jennifer E. Liu,Anita Deswal,Eric H. Yang,Bonnie Ky,Daniel J. Lenihan,Anju Nohria,Sourbha S. Dani,Sarju Ganatra +17 more
TL;DR: In this paper , a retrospective cohort analysis was performed on de-identified, aggregate patient data from the TriNetX research network, where patients ≥ 18 years of age with a history of exposure to potentially cardiotoxic antineoplastic therapy between Jan 1, 2013 and Apr 30, 2020 who subsequently developed cardiomyopathy or heart failure and treated with guideline directed medical therapy (GDMT) were identified.